MPM Capital
MPM Capital is a biotechnology investment firm that invests in early-stage companies to develop therapeutic technologies in oncology.
Business Model:
Revenue: $4.5M
Employees: 11-50
Rankings
Industries / Tags:
Detailed MPM Capital Information
Geographic Data
Address: 450 Kendall Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Twitter
Linkedin
Crunchbase
Metrics
966,501Website Global Rank
28,580Website Monthly Traffic
Twitter Followers
Description
MPM Capital is a healthcare investment firm that invests in early-stage companies developing therapeutic technologies in oncology. They invest in life sciences companies that seek to cure diseases by translating science into clinical outcomes. They prefer to invest in the biotechnology, healthcare, and life sciences sectors.
Contact Phone:
+16174259200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2003 | CryoCor | Series C | 27.5M |
| 9/2000 | CryoCor | Series A | 7M |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 1/2011 | 23andMe | Series C | 9M |
| 10/1999 | Pharmasset | Series B | 3.9M |
| 11/2002 | Critical Therapeutics,Inc. | Series A | 10M |
| 9/2008 | Valeritas | Series A | 50M |
| 10/2005 | Alinea Pharmaceuticals | Series A | 45M |
| 9/2008 | Innovative Spinal Technologies | Series C | 18M |
| 1/2006 | Xoft | Series C | 0 |
| 7/2004 | Arriva Pharmaceuticals | Series D | - |
| 5/2005 | Oxagen | Series B | 0 |
| 11/2004 | Neosil | Series A | 32M |
| 3/2016 | Tizona Therapeutics | Series B | 43M |
| 1/2017 | Maverick Therapeutics | Venture Round | 125M |
| 1/2013 | Aratana Therapeutics | Series C | 0 |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 3/2017 | Semma Therapeutics | Venture Round | - |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 8/2004 | Ceregene | Series B | 32M |
| 6/2016 | arGEN-X | Post-IPO Equity | 34.1M |
| 11/2010 | Verastem Oncology | Series A | 16M |
| 2/2006 | ARYx Therapeutics | Series E | 30.4M |
| 7/2005 | Xanodyne | Series A | 170M |
| 7/2012 | Chiasma | Series D | 38.5M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 3/2015 | Semma Therapeutics | Series A | 44M |
| 10/2013 | Mitobridge | Series A | 0 |
| 8/2020 | Trishula Therapeutics | Funding Round | - |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 2/2021 | Orna Therapeutics | Series A | 0 |
| 12/2002 | Amphora Discovery | Series B | 12.5M |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 4/2016 | Harpoon Therapeutics | Series A | 15M |
| 4/2013 | Radius Health | Private Equity Round | 43M |
| 5/2008 | SAI Life Sciences | Private Equity Round | 20M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 11/2011 | Meritage Pharma | Venture Round | 6.5M |
| 7/2009 | iPierian | Venture Round | 11.5M |
| 4/2016 | Twentyeight-Seven Therapeutics | Series A | - |
| 12/2018 | Entrada Therapeutics | Series A | 59M |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 8/2008 | Peplin | Private Equity Round | 24M |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 10/2003 | Elixir Pharmaceuticals | Series B | 40.5M |
| 11/2017 | Semma Therapeutics | Series B | 0 |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 1/2020 | BioIntervene | Series A | 30M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 10/2009 | Xanodyne | Venture Round | 0 |
| 2/2008 | Epizyme | Series A | - |
| 7/2008 | Peptimmune | Series D | 8.9M |
| 4/2002 | IntraLuminal Therapeutics | Venture Round | 20M |
| 7/2002 | ARYx Therapeutics | Series C | 25M |
| 6/2004 | ARYx Therapeutics | Series D | 55M |
| 3/2020 | ElevateBio | Series B | 170M |
| 11/2020 | Umoja Biopharma | Series A | 53M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 6/2002 | MacroGenics | Venture Round | 12.6M |
| 2/2000 | DoubleTwist | Series D | 37M |
| 7/2005 | Affymax | Series D | 60M |
| 2/2015 | Chiasma | Series E | 70M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 6/2019 | Frontier Medicines | Series A | 67M |
| 11/2006 | Chiasma | Series C | 44M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 8/2005 | Innovative Spinal Technologies | Series B | 39M |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 6/2012 | Motus Therapeutics | Series B | 25M |
| 7/2011 | Verastem Oncology | Series B | 32M |
| 1/2002 | BioXell | Series A | 19.7M |
| 5/2005 | Cellerant Therapeutics | Series B | 16M |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 3/2020 | ReCode Therapeutics | Series A | 0 |
| 12/2016 | TCR2 | Series A | 44.5M |
| 11/2008 | Pacira Pharmaceuticals | Series A | 85M |
| 9/2011 | Valeritas | Series C | 150M |
| 3/2010 | Motus Therapeutics | Series A | 21M |
| 1/2020 | Orna Therapeutics | Seed Round | 20M |
| 4/2007 | Radius Health | Series B | 57.5M |
| 4/2011 | Conatus Pharmaceuticals | Series B | 7.5M |
| 1/2011 | Aratana Therapeutics | Series A | 0 |
| 3/2015 | Clinical Ink | Venture Round | 20M |
| 3/2008 | EKR Therapeutics | Series D | 50M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 9/2007 | JapanBridge | Series A | 6.5M |
| 4/2019 | Dyne Therapeutics | Series A | 50M |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 12/2002 | Intracel Holdings Corporation | Series B | 16M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 3/2006 | Neuromed Pharmaceuticals | Series D | 0 |
| 4/2015 | True North Therapeutics | Series B | 35M |
| 9/2019 | Amphivena Therapeutics | Series C | 0 |
| 10/2003 | Cotherix | Series C | 55M |
| 6/2006 | VLST Corporation | Series B | 55M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 9/2011 | Theraclone Sciences | Series B | 10.6M |
| 7/2016 | Oncorus | Series A | 57M |
| 3/2015 | Vascular Pharmaceuticals | Series A | 9M |
| 12/2012 | 23andMe | Series D | 50M |
| 1/2008 | PrimeraDx (Primera Biosystems) | Series B | 21M |
| 11/2012 | Motus Therapeutics | Series B | 8M |
| 3/2009 | Surface Logix | Series E | 15M |
| 3/2008 | TriVascular | Series A | 65M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 8/2003 | Archus Orthopedics | Series B | 18M |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 11/2019 | Werewolf Therapeutics | Series A | 0 |
| 8/2010 | EndoGastric Solutions | Series F | 0 |
| 6/2009 | EndoGastric Solutions | Venture Round | 3.8M |
| 8/2001 | Eyetech Pharmaceuticals | Series C | 108.5M |
| 6/2020 | Cullinan Oncology | Series B | 98.5M |
| 10/2017 | Cullinan Oncology | Series A | 150M |
| 6/2018 | ITeos Therapeutics | Series B | 0 |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 1/2009 | TaiGen Biotechnology | Series C | 0 |
| 3/2004 | TaiGen Biotechnology | Series B | 0 |
| 7/2009 | PharmAthene | Post-IPO Secondary | 19.3M |
| 6/2007 | Ceregene | Series C | 0 |
| 7/2011 | Radius Health | Series C | 66M |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 9/2004 | EndoGastric Solutions | Series B | 12M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 11/2006 | Orexigen Therapeutics, Inc. | Series C | 30M |
| 12/2011 | Aratana Therapeutics | Series B | 15M |
| 3/2007 | Theraclone Sciences | Series B | 29M |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 9/2008 | Humanigen | Series D | 0 |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 7/2011 | Nevro | Series B | 58M |
| 12/2011 | Radius Health | Private Equity Round | 21.4M |
| 11/2008 | Radius Health | Series C | 15M |
| 4/2007 | Xoft | Series D | 0 |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 7/2005 | PrimeraDx (Primera Biosystems) | Series A | 11M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 1/2016 | Tizona Therapeutics | Series A | 27M |
| 9/1999 | Pointshare | Series C | 40M |
| 11/2000 | Epigenomics | Venture Round | 24.1M |
| 3/2010 | Rhythm Pharmaceuticals | Series A | 40M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 7/2005 | Peptimmune | Series C | 20.4M |
| 10/2013 | Sideris Pharmaceuticals | Series A | 32M |
| 11/2010 | Aires Pharmaceuticals | Series B | 20M |
| 3/2009 | NeoVista | Series D | 18M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2005 | Hypnion | Series B | 0 |
| 7/2014 | Valeritas | Series D | 45M |
| 4/1999 | Omrix Biopharmaceuticals | Venture Round | 20M |
| 11/2019 | SiO2 Materials Science | Venture Round | - |
| 8/2004 | Pharmasset | Series D | 40M |
| 9/2022 | Photys | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 5/2023 | ElevateBio | Series D | 0 |
| 7/2003 | Tercica | Series B | 44M |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 10/2007 | Allozyne | Series B | 30M |
| 7/2013 | InformedDNA | Seed Round | 3M |
| 12/2005 | Allozyne | Series A | 3.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 5/2009 | Elixir Pharmaceuticals | Series D | 12M |
| 3/2010 | Theraclone Sciences | Venture Round | 1.5M |
| 9/2012 | Selexys Pharmaceuticals Corporation | Series A | 23M |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 3/2016 | Potenza Therapeutics | Venture Round | 30M |
| 9/2008 | ForteBio | Series C | 25M |
| 5/2006 | MacroGenics | Series C | 45M |
| 9/2001 | MacroGenics | Series A | 13.5M |
| 4/2007 | Cellerant Therapeutics | Series B | 0 |
| 6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
| 4/2001 | Genteric | Series B | 22M |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 9/2008 | Nevro | Series A | 21.8M |
| 4/2018 | Tetherex | Series B | 50M |
| 1/2010 | Alnara Pharmaceuticals | Series B | 35M |
| 11/2003 | Neuromed Pharmaceuticals | Series C | 32M |
| 8/2007 | Neuromed Pharmaceuticals | Series E | 0 |
| 10/2009 | PrimeraDx (Primera Biosystems) | Series C | 20M |
| 10/2009 | Epizyme | Series B | 32M |
| 4/2014 | Iconic Therapeutics | Series B | 20M |
| 6/2012 | TriVascular | Series D | 60M |
| 3/2018 | TCR2 | Series B | 0 |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 3/2021 | ElevateBio | Series C | 525M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
| 9/2010 | Motus Therapeutics | Series A | 19M |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 3/2021 | Aktis Oncology | Series A | 72M |
| 3/2001 | Pharmasset | Series C | 7.4M |
| 7/2003 | Intercell | Series C | 50M |
| 10/2014 | Atopix Therapeutics | Series A | 0 |
| 11/2011 | Verastem Oncology | Series C | 20M |
| 10/2005 | Cerimon Pharmaceuticals | Series A | 70M |
| 6/2003 | Xoft | Series B | 0 |
| 10/2014 | Raze Therapeutics | Series A | 24M |
| 4/2003 | Epigenomics | Series C | 22.5M |
| 5/2002 | AVEO Oncology | Series A | 15M |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 3/2005 | Humanigen | Series B | 20M |
| 6/2003 | EndoGastric Solutions | Series A | 5M |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 11/2009 | Oxagen | Series C | 0 |
| 5/2009 | Proteon Therapeutics | Series B | 50M |
| 10/2007 | Acceleron Pharma | Series C | 31M |
| 3/2003 | Peptimmune | Series B | 41.2M |
| 2/2017 | Rhythm Pharmaceuticals | Venture Round | 41M |
| 6/2006 | Peptimmune | Series C | 0 |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 8/2010 | TriVascular | Series C | 60M |
| 11/2009 | TriVascular | Series B | 30M |
| 3/2013 | Nevro | Series C | 0 |
| 8/2000 | Syrrx | Series A | 5.1M |
| 4/2004 | Corus Pharma | Series C | 0 |
| 10/2004 | BioXell | Series C | 29M |
| 5/2010 | Ntprx | Series B | 43M |
| 11/2010 | iPierian | Series B | 29M |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 9/2012 | Vascular Pharmaceuticals | Series A | 16M |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 9/2013 | iPierian | Venture Round | 30M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2016 | Blade Therapeutics | Series B | 45M |
| 5/2014 | Proteon Therapeutics | Series D | 0 |
| 11/2013 | TriVascular | Series E | 0 |
| 7/2015 | Blade Therapeutics | Series A | 6.5M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 3/2019 | TriNetX | Series D | 40M |
| 1/2005 | CHF Solutions | Venture Round | 22.9M |
| 1/2010 | Dragonfly Sciences | Venture Round | - |
| 1/2002 | CryoCor | Series B | 12M |
| 5/2015 | Blade Therapeutics | Seed Round | - |
| 11/2006 | Solasia Pharma | Pre Seed Round | - |
| 11/2009 | EndoGastric Solutions | Series E | 0 |
| 10/2009 | EndoGastric Solutions | Venture Round | 0 |
| 2/2003 | Synergia Pharma | Series A | 2M |
| 6/2013 | Pierian Biosciences | Private Equity Round | 18M |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 6/2002 | Cardiac Dimensions | Series B | 12M |
| 10/2004 | PharmAthene | Series B | 50M |
| 12/2006 | NeoVista | Series C | 41M |
| 8/2011 | Proteon Therapeutics | Series C | 15.2M |
| 6/2007 | Athersys | Venture Round | 0 |
| 1/2002 | Archus Orthopedics | Series A | - |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 3/2003 | Hypnion | Series B | 47.5M |
| 1/2011 | Mitobridge | Seed Round | - |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 3/2004 | Restore Medical | Series C | 26.5M |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 12/2008 | Humanigen | Series D | 12M |
| 11/2008 | ARYx Therapeutics | Post-IPO Equity | 21.6M |
| 1/2012 | CoStim Pharmaceuticals | Seed Round | - |
| 4/2004 | Affymax | Series C | 20M |
| 1/2008 | Peptimmune | Series D | 8.2M |
| 12/2019 | Triplet Therapeutics | Series A | 49M |
| 6/2014 | True North Therapeutics | Series A | 22M |
| 7/2007 | Xanodyne | Series A | 25M |
| 5/2003 | Cellerant Therapeutics | Series A | 10M |
| 7/2014 | Cerecor | Series B | 32M |
| 10/2015 | 23andMe | Series E | 115M |
| 5/2001 | SenoRx | Venture Round | 19M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 9/2022 | Photys Therapeutics | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
